Ph 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda in 1L Treatment for Advanced or Metastatic MCC initiated
“The initiation of IFx-2.0’s Phase 3 accelerated approval trial is a significant milestone for TuHURA and for the 40% to 50% of patients with advanced or metastatic MCC who may not respond to first line treatment with Keytruda® (pembrolizumab),” stated James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences. “IFx-2.0’s potential ability to harness the power of a patient’s innate immune response leading to the activation and proliferation of tumor specific B cells and T cells represents a novel mechanism to overcome primary resistance to checkpoint inhibitors. As we start initiating study sites, we are grateful for the interest among investigators from leading cancer centers across the US in participating in this Phase 3 trial. We anticipate having more than half of the 22 participating sites open over the next 3-4 weeks, with the balance activated by the end of summer.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000